journal article·2021-10Open access

Systemic antiviral immunization by virus-mimicking nanoparticles-decorated erythrocytes

Lu Wang, Xinyue Wang, Fengmin Yang, Ying Liu, Lu Meng, Yan Pang, Mengmeng Zhang, Fangjie Chen, Chao Pan, Sisi Lin, Xinyuan Zhu, Kam W. Leong, Jinyao Liu

Nano Today· Volume 40

Abstract

New vaccine technologies are urgently needed to produce safe and effective vaccines in a more timely manner to prevent future infectious disease pandemics. Here, we describe erythrocyte-mediated systemic antiviral immunization, a versatile vaccination strategy that boosts antiviral immune responses by using erythrocytes decorated with virus-mimetic nanoparticles carrying a viral antigen and a Toll-like receptor (TLR) agonist. As a proof of concept, polydopamine nanoparticles were synthesized via a simple in situ polymerization in which the nanoparticles were conjugated with the SARS-CoV-2 spike protein S1 subunit and the TLR7/8 agonist R848. The resulting SARS-CoV-2 virus-mimetic nanoparticles were attached to erythrocytes via catechol groups on the nanoparticle. Erythrocytes naturally home to the spleen and interact with the immune system. Injection of the nanoparticle-decorated erythrocytes into mice resulted in greater maturation and activation of antigen-presenting cells, humoral and cellular immune responses in the spleen, production of S1-specific immunoglobulin G (IgG) antibodies, and systemic antiviral T cell responses than a control group treated with the nanoparticles alone, with no significant negative side effects. These results show that erythrocyte-mediated systemic antiviral immunization using viral antigen- and TLR agonist-presenting polydopamine nanoparticles-a generalizable method applicable to many viral infections-is effective new approach to developing vaccines against severe infectious diseases.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Respiratory viral infections research · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (59)

Show source-provided references
1. Duration of antiviral immunity after smallpox vaccination10.1038/nm917 ↗
2. A blueprint for HIV vaccine discovery10.1016/j.chom.2012.09.008 ↗
3. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus10.3389/fmicb.2019.01781 ↗
4. WHO, https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19–13-april-2021, 2020.
5. Sensitive, rapid, low-cost, and multiplexed COVID-19 monitoring by the wireless telemedicine platform10.1016/j.matt.2020.11.001 ↗
6. Covid-19: four fifths of cases are asymptomatic, China figures indicate10.1136/bmj.m1375 ↗
7. COVID-19 vaccine development and a potential nanomaterial path forward10.1038/s41565-020-0737-y ↗
8. Engineering antiviral vaccines10.1021/acsnano.0c06109 ↗
9. Evolutionary reversion of live viral vaccines: can genetic engineering subdue it?10.1093/ve/vev005 ↗
10. Vaccine adjuvants: putting innate immunity to work10.1016/j.immuni.2010.10.002 ↗
11. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity10.4049/jimmunol.172.10.6290 ↗
12. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells10.4049/jimmunol.161.8.4023 ↗
13. Interactions of engineered nanoparticles with organs protected by internal biological barriers10.1002/smll.201201463 ↗
14. Applications of nanotechnology for immunology10.1038/nri3488 ↗
15. Improving cancer immunotherapy through nanotechnology10.1038/s41568-019-0186-9 ↗
16. Nanotechnology for COVID-19: therapeutics and Vaccine Research10.1021/acsnano.0c04006 ↗
17. COVID-19 vaccine frontrunners and their nanotechnology design10.1021/acsnano.0c07197 ↗
18. Nanoparticle formulated vaccines: opportunities and challenges10.1039/C9NR08958F ↗
19. The role of the spleen in resistance to infection10.1146/annurev.me.37.020186.000405 ↗
20. The who, how and where of antigen presentation to B cells10.1038/nri2454 ↗
21. From the cradle to the grave: the role of macrophages in erythropoiesis and erythrophagocytosis10.3389/fimmu.2017.00073 ↗
22. Mechanisms and pathways for the clearance of bacteria from blood circulation in health and disease10.1016/j.pathophys.2016.03.001 ↗
23. Phagocytosis and oxycytosis: two arms of human innate immunity10.1007/s12026-018-8988-5 ↗
24. Of macrophages and red blood cells; a complex love story10.3389/fphys.2014.00009 ↗
25. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude10.1038/s41467-018-05079-7 ↗
26. Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator10.1161/CIRCULATIONAHA.107.750257 ↗
27. Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease10.1073/pnas.1701746114 ↗
28. Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function10.1073/pnas.2002880117 ↗
29. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation10.1126/science.abb2507 ↗
30. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE210.1126/science.abb2762 ↗
31. The 2019-new coronavirus epidemic: evidence for virus evolution10.1002/jmv.25688 ↗
32. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic
33. Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus)10.1016/j.dci.2014.11.018 ↗
34. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells10.1084/jem.20091181 ↗
35. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques10.1128/JVI.03309-13 ↗
36. Immune-mediated approaches against COVID-1910.1038/s41565-020-0732-3 ↗
37. Polydopamine as the antigen delivery nanocarrier for enhanced immune response in tumor immunotherapy10.1021/acsbiomaterials.9b00359 ↗
38. Bioinspired catecholic chemistry for surface modification10.1039/c1cs15026j ↗
39. The effect of polymeric nanoparticles on biocompatibility of carrier red blood cells
40. Dendritic cells and the control of immunity10.1038/32588 ↗
41. Antigen presentation and T cell stimulation by dendritic cells10.1146/annurev.immunol.20.100301.064828 ↗
42. Phagocytosis and antigen presentation in dendritic cells10.1111/j.1600-065X.2007.00552.x ↗
43. Pathogen-mimicking polymeric nanoparticles based on dopamine polymerization as vaccines adjuvants induce robust humoral and cellular immune responses10.1002/smll.201503662 ↗
44. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation10.1016/S1074-7613(00)80333-7 ↗
45. Herpes simplex virus 1 ICP22 suppresses CD80 expression by murine dendritic cells10.1128/JVI.01803-18 ↗
46. Adipocytes as anticancer drug delivery depot10.1016/j.matt.2019.08.007 ↗
47. CpG DNA induces stronger immune responses with less toxicity than other adjuvants10.1016/S0264-410X(99)00526-5 ↗
48. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery10.1016/j.vaccine.2003.09.052 ↗
49. Humoral innate immune response and disease10.1016/j.clim.2012.06.002 ↗
50. Antigen extraction and B cell activation enable identification of rare membrane antigen specific human B cells10.3389/fimmu.2019.00829 ↗
51. Regulation of the germinal center response10.3389/fimmu.2018.02469 ↗
52. Clinical characteristics of coronavirus disease 2019 in China10.1056/NEJMoa2002032 ↗
53. The trinity of COVID-19: immunity, inflammation and intervention10.1038/s41577-020-0311-8 ↗
54. The role of IFN-gamma in immune responses to viral infections of the central nervous system10.1016/S1359-6101(02)00044-8 ↗
55. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria10.4049/jimmunol.178.5.3126 ↗
56. Antiviral actions of interferons10.1128/CMR.14.4.778-809.2001 ↗
57. Potential role of interferons in treating COVID-19 patients10.1016/j.intimp.2020.107171 ↗
58. Erythrocyte-inspired delivery systems10.1002/adhm.201200138 ↗
59. Polydopamine-mediated surface modification of scaffold materials for human neural stem cell engineering10.1016/j.biomaterials.2012.06.067 ↗